• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Alex Morozov

Related Topics

  1. Matthew Coffina
  2. Damien Conover
  3. Morningstar.com
  4. Morningstar Fund Analysts
  5. Jeremy Glaser
  6. Paul Larson

Popular Topics

  1. Eagle Bulk Shipping
  2. Natural Gas
  3. India
  4. Asia
  5. France

Alex Morozov

  1. All
  2. Videos
  3. Investing
  1. Finding Value in Health Care After the Election

    Tuesday's election eliminated some uncertainty around health-care reform, but the market is still undervaluing several firms in the sector, say Morningstar's Alex Morozov and Matt Coffina.

  2. Why J&J Bought a Big Piece of Elan

    Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.

  3. After Reform, Opportunity

    Associate director for health-care analysis Alex Morozov on the uncertainty-overhang relief, biggest winners, and best values in post-reform health care.

  4. Will Life Sciences Firms Fall Off the Fiscal Cliff?

    Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.

  5. June/July 2012 Picks

    Four offerings deemed to be right for right now.

  6. 5 Election Takeaways for Investors

    Morningstar markets editor Jeremy Glaser sizes up the scenarios on the fiscal cliff, health-care reform, Fed policy, bank regulation, and more following this week's election.

  7. Health Care’s Outlook Clarifies

    Obamacare will benefit some sectors more than others, but poor economy and pricing pressures are the biggest challenges most health-care firms must face.

  8. Roundup From the Morningstar ETF Invest Conference 2011

    Morningstar hosted its second ETF Invest Conference Sept. 22-23 in Chicago.

  9. Will Reform Put a Target on Pharma's Back?

    Morningstar's Damien Conover says that current reform proposals are more like a slingshot than a rifle aimed at pharmaceutical companies--which are currently priced for a worst-case scenario.

  10. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

12
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.